A Golden Hour and Golden Opportunity for β-Cell Preservation.
作者信息
Evans-Molina Carmella, Oram Richard A
机构信息
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
出版信息
Diabetes. 2024 Jun 1;73(6):834-836. doi: 10.2337/dbi24-0019.
Abstract
摘要
相似文献
1
A Golden Hour and Golden Opportunity for β-Cell Preservation.β细胞保护的黄金一小时与黄金机遇。
Diabetes. 2024 Jun 1;73(6):834-836. doi: 10.2337/dbi24-0019.
2
Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.用于1型糖尿病病情改善的新型免疫疗法
Drugs. 2025 Apr;85(4):457-473. doi: 10.1007/s40265-025-02150-8. Epub 2025 Jan 28.
3
Diabetes treatments near and far.远近皆有的糖尿病治疗方法。
Nat Biotechnol. 1996 Apr;14(4):428. doi: 10.1038/nbt0496-428b.
4
Preservation of beta cell function.β细胞功能的保存。
Pediatr Diabetes. 2010 May;11(3):152-3. doi: 10.1111/j.1399-5448.2010.00675.x.
5
FDA approves teplizumab: a milestone in type 1 diabetes.美国食品药品监督管理局批准替普珠单抗：1型糖尿病领域的一个里程碑。
Lancet Diabetes Endocrinol. 2023 Jan;11(1):18. doi: 10.1016/S2213-8587(22)00351-5. Epub 2022 Nov 24.
6
An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.用于治疗新冠肺炎的巴尼韦单抗-A单克隆抗体紧急使用授权。
JAMA. 2021 Mar 2;325(9):880-881. doi: 10.1001/jama.2020.24415.
7
The future is on the way: β cell function preservation for type 1 diabetes.未来已来：1 型糖尿病β细胞功能保护。
Med. 2024 Jan 12;5(1):4-6. doi: 10.1016/j.medj.2023.11.003.
8
Sanofi to propel inhalable insulin Afrezza into market.赛诺菲将推动可吸入胰岛素Afrezza进入市场。
Nat Biotechnol. 2014 Sep;32(9):851-2. doi: 10.1038/nbt0914-851a.
9
Alzheimer's drug approvals create prescribing dilemmas.阿尔茨海默病药物的获批引发了处方难题。
Science. 2024 Nov;386(6721):472-473. doi: 10.1126/science.adu2383. Epub 2024 Oct 31.
10
Anti-CD3 drug keeps diabetes at bay.抗CD3药物可预防糖尿病。
Nat Biotechnol. 2019 Oct;37(10):1099-1101. doi: 10.1038/d41587-019-00025-4.
引用本文的文献
1
Call for Standardization of C-Peptide Measurement.呼吁规范C肽检测
J Diabetes Sci Technol. 2025 Aug 8:19322968251362848. doi: 10.1177/19322968251362848.
2
The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum.1型糖尿病的异质性：对发病机制、预防和治疗的影响——2024年糖尿病、糖尿病护理与糖尿病学专家论坛
Diabetologia. 2025 Jul 30. doi: 10.1007/s00125-025-06462-y.
3
A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies.一项关于新诊断1型糖尿病患者中保护胰岛素分泌β细胞功能干预措施的系统评价和网状荟萃分析：免疫调节疗法随机对照试验的结果
BMC Med. 2025 Jul 1;23(1):351. doi: 10.1186/s12916-025-04201-z.
4
Harnessing Machine Learning, a Subset of Artificial Intelligence, for Early Detection and Diagnosis of Type 1 Diabetes: A Systematic Review.利用机器学习（人工智能的一个子集）进行1型糖尿病的早期检测与诊断：一项系统评价
Int J Mol Sci. 2025 Apr 22;26(9):3935. doi: 10.3390/ijms26093935.
5
Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.用于1型糖尿病病情改善的新型免疫疗法
Drugs. 2025 Apr;85(4):457-473. doi: 10.1007/s40265-025-02150-8. Epub 2025 Jan 28.
本文引用的文献
1
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes.证据表明 C 肽可作为验证性替代指标，用于预测 1 型糖尿病疾病修饰治疗试验中的临床获益。
Diabetes. 2024 Jun 1;73(6):823-833. doi: 10.2337/dbi23-0012.
2
Prevention of cardiorenal complications in people with type 2 diabetes and obesity.预防 2 型糖尿病和肥胖患者的心肾并发症。
Cell Metab. 2024 Feb 6;36(2):338-353. doi: 10.1016/j.cmet.2023.12.018. Epub 2024 Jan 9.
3
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.一种标准化指标，用于增强 1 型糖尿病临床试验设计和结果解读。
Nat Commun. 2023 Nov 8;14(1):7214. doi: 10.1038/s41467-023-42581-z.
4
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.在新诊断 1 型糖尿病疾病修正治疗试验中 C 肽与代谢结局：一项个体参与者荟萃分析。
Lancet Diabetes Endocrinol. 2023 Dec;11(12):915-925. doi: 10.1016/S2213-8587(23)00267-X. Epub 2023 Nov 3.
5
Teplizumab approval for type 1 diabetes in the USA.替普珠单抗在美国获批用于1型糖尿病。
Lancet Diabetes Endocrinol. 2023 Feb;11(2):76-77. doi: 10.1016/S2213-8587(22)00390-4. Epub 2023 Jan 6.
6
Endpoints for clinical trials in ophthalmology.眼科临床试验的终点。
Prog Retin Eye Res. 2023 Nov;97:101160. doi: 10.1016/j.preteyeres.2022.101160. Epub 2023 Jan 2.
7
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.2021 年全球 1 型糖尿病发病率、患病率和死亡率，并预测至 2040 年：一项建模研究。
Lancet Diabetes Endocrinol. 2022 Oct;10(10):741-760. doi: 10.1016/S2213-8587(22)00218-2. Epub 2022 Sep 13.
8
Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia.长期 1 型糖尿病患者β细胞功能残留与低血糖发生率降低有关。
J Clin Invest. 2021 Feb 1;131(3). doi: 10.1172/JCI143011.
9
A quantitative measure of treatment response in recent-onset type 1 diabetes.近期发病的1型糖尿病治疗反应的定量测量。
Endocrinol Diabetes Metab. 2020 May 14;3(3):e00143. doi: 10.1002/edm2.143. eCollection 2020 Jul.
10
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.1型糖尿病症状前分期：美国青少年糖尿病研究基金会、美国内分泌学会及美国糖尿病协会的科学声明
Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419.
Zotero 插件